Type of non Hodgkin's lymphoma-Diffuse large B-cell lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Diffuse large B-cell lymphoma Posts on Medivizor

Evaluating mental performance in older survivors of non-Hodgkin lymphoma

Posted by on Feb 22, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated mental functioning in older survivors of non-Hodgkin lymphoma (NHL). This study concluded that these individuals may have some mental function decline and lower mental function compared to individuals who did not have cancer. Some background Research suggests that cancer treatments have been shown to cause...

Read More

Comparing different sources for stem cell transplantation for patients with lymphoma

Posted by on Feb 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the outcomes of patients with lymphoma who had an allogeneic stem cell transplant with different sources of stem cells. This study found that stem cells from a matching donor had better outcomes compared to those from unrelated cord blood. Some background Allogeneic stem cell transplantation is one type of stem cell...

Read More

Evaluating high-dose methotrexate plus chemotherapy for patients with diffuse large B-cell lymphoma

Posted by on Feb 16, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of treatment with high-dose methotrexate (Trexall) plus chemotherapy for diffuse B-cell lymphoma (DLBCL). This study concluded that this regimen was promising, with manageable side effects for these patients. Some background DLBCL is the most common type of non-Hodgkin’s lymphoma. Initial treatment...

Read More

Evaluating high-dose cyclophosphamide for patients with hard-to-treat B-cell non-Hodgkin’s lymphoma

Posted by on Jan 12, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of high-dose cyclophosphamide (Cytoxan) for the treatment of relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that high-dose cyclophosphamide was safe and effective for these patients. Some background Chemotherapy regimens remain a standard treatment...

Read More

Trends in outcomes of allogeneic transplantation for elderly patients with non-Hodgkin lymphoma

Posted by on Dec 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of allogeneic stem cell transplants (allo-SCT) in elderly patients with non-Hodgkin’s lymphoma (NHL). This study found that allo-SCT has improved survival outcomes for these patients. Some background Allogeneic stem cell transplantation (allo-SCT) can be highly effective for patients with...

Read More

What factors can predict the success of stem cell transplantation for patients with non-Hodgkin lymphoma?

Posted by on Nov 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the risk factors associated with delayed engraftment (DE) in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some background...

Read More

Can FDG-PET/CT scanning predict treatment outcomes in diffuse large B-cell lymphoma?

Posted by on Oct 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated whether FDG-PET/CT imaging during treatment helped predict outcomes for patients with diffuse large B-cell lymphoma (DLBCL). The authors concluded that mid-treatment imaging might help determine disease status rather than guide treatment decisions. Some background DLBCL is the most common type of...

Read More

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Evaluating blinatumomab for patients with recurrent or non-responsive non-Hodgkin’s lymphoma

Posted by on Sep 13, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term safety and effectiveness of blinatumomab (Blincyto) for non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The authors concluded that blinatumomab showed promising effectiveness for these patients, with minimal side effects. Some background Chemoimmunotherapy...

Read More

Evaluating the risk of secondary cancers from infections in patients with non-Hodgkin’s lymphoma

Posted by on Aug 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined whether there is a link between the type of non-Hodgkin’s lymphoma (NHL) and the development of secondary cancer due to certain infections.  The authors concluded that patients with diffuse large B-cell lymphoma (DLBCL) or marginal zone lymphoma (MZL) may be at risk for developing a second type of...

Read More

Using liver AST levels to predict outcomes for patients with diffuse large B-cell lymphoma

Posted by on Jun 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the impact of aspartic transaminase (AST) levels in the blood on survival outcomes for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that high levels of AST in the blood were associated with poorer treatment outcomes for these patients. Some background DLBCL is one of the most common types...

Read More